About this trial
This project aims to identify key cells and molecules involved in the development and modulation of neuropathic pain treated with spinal cord stimulation (SCS). By measuring concentrations of selected inflammatory mediators and signaling molecules (e.g., IL-1β, IL-6, IL-17, IL-33, BDNF, VEGF, GABA) in the blood and cerebrospinal fluid (CSF) of patients undergoing SCS, the study seeks to better understand the mechanism of action of SCS. The findings may allow the development of predictive biomarkers, help tailor stimulation parameters, and support complementary pharmacotherapy. The project also explores differences in response to various stimulation types and the role of glial cells in SCS efficacy, with a view to improving patient outcomes through more personalized neuromodulation strategies.
Eligibility criteria
Qualifiers
Age 18-80
PSPS or CRPS
Neuropathic pain for at least 6 months
Disqualifiers
Drug/alcohol addiction
Malignant tumour
Psychiatric disorders
Active infection
Trial design
Treatments tested in this trial
- Immunological Factors
Treatment groups
Sponsors and collaborators
Pawel Sokal
Lead sponsor
Jan Biziel University Hospital No 2 in Bydgoszcz
Sponsor institution
Department of Neurosurgery Collegium Medicum Nicolaus Copernicus University
Collaborator
Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz
Collaborator